Product image of Lacosamid Vivanta (Lacosamide) supplied by GNH India

Lacosamid Vivanta

Active Ingredient:
Lacosamide
Origin:
EU

Lacosamid Vivanta (Lacosamide)

Lacosamide, the active ingredient in Lacosamid Vivanta, is an anticonvulsant presented as an oral tablet for oral use. The product complies with EU quality standards and is manufactured under GMP conditions. It is indicated for the treatment of partial‑onset seizures in patients with epilepsy.

GNH India supplies Lacosamid Vivanta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company provides regulatory‑approved documentation and supports global distribution through established logistics networks.

Manufacturer / TM Owner

Vivanta Generics S.R.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lacosamide is used to control seizure activity within the focal seizure pathway of epilepsy.

  • Partial‑onset seizures: reduces the frequency and severity of focal seizures in patients with epilepsy.
  • Focal seizures: provides adjunctive therapy to achieve better seizure control.
  • Epilepsy (overall): incorporated into broader treatment regimens to manage epilepsy when focal seizures are present.

How It Works

  • Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes, stabilizing hyperexcitable neuronal membranes and decreasing repetitive neuronal firing. This modulation reduces the propagation of epileptiform activity without affecting normal neuronal conduction, thereby contributing to seizure control in focal epilepsy.

Side Effects

Lacosamide may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects

  • Dizziness: transient sensation of light‑headedness.
  • Headache: mild to moderate pain in the head region.
  • Nausea: occasional upset stomach.
  • Fatigue: feeling unusually tired.
  • Blurred vision: temporary visual disturbances.
  • Diplopia: double vision in some patients.

Serious or Rare Side Effects

  • Cardiac arrhythmias: including PR‑interval prolongation.
  • Severe rash or hypersensitivity reactions: such as Stevens‑Johnson syndrome.
  • Suicidal thoughts or behavior: emergent mood changes requiring immediate evaluation.
  • Hepatic injury: elevated liver enzymes or hepatitis.
  • Severe dizziness leading to falls.
  • Anaphylaxis: rare but life‑threatening allergic response.

Precautions & Warnings

When prescribing Lacosamid Vivanta, clinicians should consider several safety precautions.

  • Renal impairment: adjust dose in patients with reduced renal function.
  • Hepatic impairment: monitor liver enzymes in patients with liver disease.
  • Cardiac conduction disorders: avoid in patients with known PR‑interval prolongation.
  • Pregnancy: safety unknown; weigh benefits against potential risks.
  • Driving and operating machinery: caution due to possible dizziness or visual disturbances.
  • Store at room temperature: keep in the original container, protect from moisture and light.

Avoid Interactions

Lacosamide can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid)

  • Concomitant use with other sodium‑channel blockers (e.g., carbamazepine, phenytoin) may increase risk of cardiac arrhythmias.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can lower lacosamide plasma concentrations.
  • Excessive alcohol intake: may enhance central nervous system depression.

Moderate Interactions (Monitor Closely)

  • Hormonal contraceptives: lacosamide may reduce effectiveness; consider alternative contraception.
  • Other antiepileptic drugs (e.g., valproate, levetiracetam): monitor seizure control and side‑effect profile.
  • Antidepressants (e.g., SSRIs): observe for additive dizziness or sedation.

Frequently Asked Questions

Lacosamid Vivanta contains lacosamide, an anticonvulsant indicated for the treatment of partial‑onset (focal) seizures in patients with epilepsy. It is used as part of a broader seizure‑control regimen to reduce seizure frequency and severity.

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. By stabilizing hyperexcitable neurons, it reduces repetitive firing and the spread of epileptiform activity, thereby helping to control focal seizures.

The dose of Lacosamid Vivanta is individualized. A qualified prescriber determines the appropriate starting dose and titration schedule based on the patient’s clinical condition, response, and any relevant renal or hepatic considerations.

Safety data for lacosamide in pregnancy and lactation are limited, and the product’s pregnancy category is unknown. Use only if the potential benefit justifies the potential risk to the fetus or infant, and discuss options with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from many traditional agents that target fast inactivation. Compared with drugs such as carbamazepine, lacosamide may have a lower risk of drug‑induced hyponatremia and offers a distinct side‑effect profile, though individual response varies.

Lacosamid Vivanta should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

The medication is supplied as an oral tablet. Patients should swallow the tablet whole with water, with or without food, as directed by their prescriber. Consistent administration timing helps maintain stable drug levels.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions (e.g., Stevens‑Johnson syndrome), suicidal ideation, and significant hepatic injury. Patients should be monitored for these signs, and any concerning symptoms warrant immediate medical evaluation.

Lacosamid Vivanta is contraindicated in individuals with known hypersensitivity to lacosamide or any excipients, and in patients with significant cardiac conduction disorders (e.g., marked PR‑interval prolongation). Caution is also advised for those with severe renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.